1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,202 | 0,218 | 22.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| Di | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 356 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 16.02. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 16.02. | VIVA BIOTECH (01873): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 29.01. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx | ||
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 268 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 449 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12.25 | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| 29.09.25 | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 346 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 25.09.25 | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09.25 | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 311 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08.25 | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 469 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 15.05.25 | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 423 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 28.03.25 | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 474 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03.25 | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 262 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,500 | -0,44 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| NOVONESIS | 46,340 | -0,41 % | Dividendenbekanntmachungen (20.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,15 USD 0,1295 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0647 EUR AL SYDBANK... ► Artikel lesen | |
| GENMAB | 219,40 | +1,11 % | Passing of Genmab A/S' Annual General Meeting | Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,688 | -0,05 % | Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus | WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 242,00 | +1,68 % | Jefferies cuts BeOne Medicines stock rating on valuation concerns | ||
| SINO BIOPHARM | 0,660 | +2,26 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TRD221 "COMPLEMENT PROTEIN MODULATOR" APPROVED BY THE NMPA | ||
| VERICEL | 29,200 | +7,35 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,065 | -0,24 % | Moleculin Biotech, Inc.: Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 | Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech,... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,302 | 0,00 % | Energiekrise treibt Agrar-Wende: Satte Kursgewinne mit MustGrow Biologics, K+S und Corteva Agriscience | Die Landwirtschaft steht vor einer Zäsur. Der Grund: Die jüngste Eskalation im Nahen Osten. Die Straße von Hormus, durch die ein Fünftel des weltweiten Flüssigerdgas-Handels und signifikante Teile der... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 31,650 | +3,60 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| ZAI LAB LTD ADR | 15,700 | -0,63 % | ZAI LAB (09688): NOTICE OF BOARD ACTION | ||
| BIOXCEL THERAPEUTICS | 1,372 | +4,10 % | BioXcel Therapeutics stock initiated with buy rating at Rodman | ||
| REGENXBIO | 7,000 | -0,71 % | Regenxbio und GlaxoSmithKline beenden Streit um Lizenzgebühren mit 10-Millionen-Dollar-Vergleich | ||
| AKEBIA | 1,233 | +1,15 % | Akebia Therapeutics, Inc.: Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 | ||
| ZEVRA THERAPEUTICS | 8,150 | +1,88 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,77 % bei einem Aktienkurs von 0,204 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.